

NOTIFICATION BY PRIMARY INSIDERS/RELATED PARTIES TO LYTIX BIOPHARMA AS

1	Details of the Primary Insider/Related Party					
a)	Name	Øystein Rekdal				
2	Reason for the notification					
a)	Position/status	Chief Executive Officer				
b)	Initial notification/ Amendment	Initial notification				
3	Details of the company					
a)	Name	Lytix Biopharma AS				
b)	LEI	549300NXMIMRMRBCDZ071				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument	Shares Options related to shares in Lytix Biopharma AS with ISIN NO0010405780				
b)	Nature of the transaction	Grant of share options				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>1,627,860</td> </tr> </tbody> </table>	Price(s)	Volume(s)	0	1,627,860
Price(s)	Volume(s)					
0	1,627,860					
d)	Aggregated information — Aggregated volume — Price	Receipt of 1,627,860 options for a total consideration of NOK 0. A strike price must be paid upon exercise of the options.				
e)	Date of the transaction	2025-09-01				
f)	Place of transaction	XOFF - Outside a trading venue				

1	Details of the Primary Insider/Related Party					
a)	Name	Baldur Sveinbjørnsson				
2 Reason for the notification						
a)	Position/status	Chief Scientific Officer				
b)	Initial notification/ Amendment	Initial notification				
3 Details of the company						
a)	Name	Lytix Biopharma AS				
b)	LEI	549300NXMIMRSBCDZ071				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument	Shares Options related to shares in Lytix Biopharma AS with ISIN NO0010405780				
b)	Nature of the transaction	Grant of share options				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>923,930</td> </tr> </tbody> </table>	Price(s)	Volume(s)	0	923,930
Price(s)	Volume(s)					
0	923,930					
d)	Aggregated information — Aggregated volume — Price	Receipt of 923,930 options for a total consideration of NOK 0. A strike price must be paid upon exercise of the options.				
e)	Date of the transaction	2025-09-01				
f)	Place of transaction	XOFF - Outside a trading venue				

1	Details of the Primary Insider/Related Party					
a)	Name	Gjest Breistein				
2 Reason for the notification						
a)	Position/status	Chief Financial Officer				
b)	Initial notification/ Amendment	Initial notification				
3 Details of the company						
a)	Name	Lytix Biopharma AS				
b)	LEI	549300NXMIMRSBCDZ071				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument	Shares Options related to shares in Lytix Biopharma AS with ISIN NO0010405780				
b)	Nature of the transaction	Grant of share options				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>615,620</td> </tr> </tbody> </table>	Price(s)	Volume(s)	0	615,620
Price(s)	Volume(s)					
0	615,620					
d)	Aggregated information — Aggregated volume — Price	Receipt of 615,620 options for a total consideration of NOK 0. A strike price must be paid upon exercise of the options.				
e)	Date of the transaction	2025-09-01				
f)	Place of transaction	XOFF - Outside a trading venue				

1	Details of the Primary Insider/Related Party					
a)	Name	Mette Husbyn				
2 Reason for the notification						
a)	Position/status	Chief Technology Officer				
b)	Initial notification/ Amendment	Initial notification				
3 Details of the company						
a)	Name	Lytix Biopharma AS				
b)	LEI	549300NXMIMRSBCDZ071				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument	Shares Options related to shares in Lytix Biopharma AS with ISIN NO0010405780				
b)	Nature of the transaction	Grant of share options				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>341,310</td> </tr> </tbody> </table>	Price(s)	Volume(s)	0	341,310
Price(s)	Volume(s)					
0	341,310					
d)	Aggregated information — Aggregated volume — Price	Receipt of 341,310 options for a total consideration of NOK 0. A strike price must be paid upon exercise of the options.				
e)	Date of the transaction	2025-09-01				
f)	Place of transaction	XOFF - Outside a trading venue				